Interleukin-12 gene therapy in combination with bevacizumab and pegylated liposomal doxorubicin for treatment of disseminated ovarian cancer

被引：0
|
作者：
Fewell, Jason G.
Matar, Majed M.
Rice, Jennifer
McClure, Diane
Brunhoeber, Elaine
Sparks, Jeff
Greenleaf, Stefanie
Smith, Kelley
Anwer, Khursheed
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2078
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells
    Marczak, Agnieszka
    Denel, Marta
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (03): : 149 - 152
  • [32] Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer
    Rose, PG
    ONCOLOGIST, 2005, 10 (03): : 205 - 214
  • [33] Pembrolizumab plus pegylated liposomal Doxorubicin for Patients with Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (01) : 19 - 20
  • [34] Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
    Monk, Bradley J.
    Herzog, Thomas J.
    Kaye, Stanley B.
    Krasner, Carolyn N.
    Vermorken, Jan B.
    Muggia, Franco M.
    Pujade-Lauraine, Eric
    Lisyanskaya, Alla S.
    Makhson, Anatoly N.
    Rolski, Janusz
    Gorbounova, Vera A.
    Ghatage, Prafull
    Bidzinski, Mariusz
    Shen, Keng
    Ngan, Hextan Yuen-Sheung
    Vergote, Ignace B.
    Nam, Joo-Hyun
    Park, Youn Choi
    Lebedinsky, Claudia A.
    Poveda, Andres M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3107 - 3114
  • [35] Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
    Jones, Robin L.
    Herzog, Thomas J.
    Patel, Shreyaskumar R.
    von Mehren, Margaret
    Schuetze, Scott M.
    Van Tine, Brian A.
    Coleman, Robert L.
    Knoblauch, Roland
    Triantos, Spyros
    Hu, Peter
    Shalaby, Waleed
    McGowan, Tracy
    Monk, Bradley J.
    Demetri, George D.
    CANCER MEDICINE, 2021, 10 (11): : 3565 - 3574
  • [36] Interstitial Pneumonitis after Treatment with Bevacizumab and Pegylated Liposomal Doxorubicin in a Patient with Metastatic Breast Cancer
    Huober, Jens
    Schoch, Otto
    Templeton, Arnoud
    Spirig, Christian
    Thuerlimann, Beat
    CHEMOTHERAPY, 2010, 56 (01) : 69 - 70
  • [37] Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients
    Bourgeois, Hugues
    Joly, Florence
    Pujade-Lauraine, Eric
    Cure, Herve
    Guastalla, Jean Paul
    Ferru, Aurelie
    Chabrun, Virginie
    Chieze, Stephanie
    Tourani, Jean-Marc
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 399 - 404
  • [38] Pegylated liposomal doxorubicin in ovarian cancer patients with renal compromise
    Basu, C. K.
    Mukhopadhyay, A.
    Pandey, R.
    Dey, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer
    Lorusso, D
    Ferrandina, G
    Lo Voi, R
    Fagotti, A
    Scambia, G
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 98 - 103
  • [40] EFFECTIVENESS AND TOXICITY OF PEGYLATED LIPOSOMAL DOXORUBICIN FOR ADVANCED OVARIAN CANCER
    Sequeira, I.
    Simas, A.
    Brandao, M.
    Savva-Bordalo, J.
    Pereira, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1491 - 1491
12345